#United States #Tampa General Hospital #Tampa, Florida #Cancer Institute #Boris Naraev

Dr. Boris Naraev Joins TGH Cancer Institute

Tampa General Hospital (TGH) has announced a significant addition to its Cancer Institute, appointing Dr. Boris Naraev, a renowned medical oncologist with a focus on gastrointestinal, neuroendocrine, and endocrine cancers. His expertise will enhance the fight against some of the most challenging cancers in the Tampa Bay area.

A Leader in Oncology

Dr. Naraev is celebrated for his impressive academic credentials and a history of clinical research that marks him as a national leader in the highly specialized fields of neuroendocrine and endocrine cancers. Before joining TGH, he spearheaded the Gastrointestinal, Neuroendocrine and Rare Cancers Program at the Anderson Family Cancer Institute in Jupiter, Florida. He also played a pivotal role at the Banner MD Anderson Cancer Center in Phoenix, where he was instrumental in developing one of the West's largest neuroendocrine cancer programs.

Accruing his medical qualifications from the Orenburg State Medical Academy in Russia, where he graduated summa cum laude and achieved a Doctor of Philosophy in Medical Sciences, Dr. Naraev brings a wealth of knowledge directly related to patient care and innovative approaches in cancer treatment.

Strengthening Cancer Care in Tampa

Dr. Eduardo M. Sotomayor, vice president and executive director of the TGH Cancer Institute, hailed Dr. Naraev’s arrival as a game changer in treating patients grappling with hard-to-treat cancers. “His commitment to clinical excellence and research will not only propel advances in patient care but also amplify our capabilities in providing groundbreaking therapies,” said Sotomayor.

Dr. Naraev joins fellow medical oncologist Dr. Noman Ashraf, who expressed enthusiasm about the new collaboration. Together, they aim to deliver cutting-edge treatment plans while leveraging Dr. Naraev's broad spectrum of clinical trials designed for patients with complex health concerns.

The Role of Endocrine and Neuroendocrine Tumors

Endocrine tumors can originate from hormone-producing glands, including the thyroid, adrenal, and pancreas, while neuroendocrine tumors are rarer, arising from neuroendocrine cells. The TGH Cancer Institute’s faculty is banking on Dr. Naraev’s drive to accelerate the introduction of innovative clinical trials that could transform the treatment landscape for these cancers.

Dr. Richard Tuli, deputy director of the TGH Cancer Institute, emphasized Dr. Naraev’s expertise in radiopharmaceutical therapy, a specialization that is increasingly critical in modern oncological practices. “We are indeed fortunate to have such a gifted leader among our ranks,” remarked Tuli.

Commitment to Patient-Centric Care

Dr. Naraev expressed immediate admiration for the TGH Cancer Institute's mission and approach to patient care, reflecting a shared vision for achieving health outcomes that emphasize compassion alongside clinical excellence. His aspiration is to not only contribute to science and education but also to make a significant impact on patient lives in a supportive environment.

The inclusion of Dr. Naraev correlates with TGH's aim to solidify its position among America's foremost health care centers, as articulated by Dr. Abraham Schwarzberg, executive vice president and chief of Oncology. His belief is rooted in the strategic integration of top-tier professionals to ensure that every patient has access to world-class treatments.

The TGH Cancer Institute, recognized among the top 50 cancer centers nationally by U.S. News & World Report, has made significant strides in providing comprehensive patient care through innovative therapies and rigorous diagnostic techniques. This distinguished reputation is backed by various accreditations and the institute's commitment to community health education initiatives.

For those seeking exceptional care for cancer treatment, the TGH Cancer Institute stands at the forefront, equipped with the latest advances in medical technology, commitment to clinical trials, and a compassionate approach to healthcare.

For further inquiries or information about TGH Cancer Institute services, visit www.tgh.org/cancer.